Welcome to our dedicated page for Immatics N.V SEC filings (Ticker: IMTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Immatics N.V. (IMTX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on NASDAQ. Immatics files annual reports under Form 20‑F and furnishes current information on Form 6‑K, giving investors structured insight into its clinical programs, collaborations and financial position.
Recent Form 6‑K reports describe interim financial results, business updates and detailed clinical data for Immatics’ PRAME‑focused pipeline. These filings include summaries of Phase 1a and 1b trials for the second‑generation PRAME cell therapy IMA203CD8 in solid tumors, the IMA402 PRAME TCR Bispecific, and the IMA401 MAGEA4/8 TCR Bispecific, along with information on tolerability, response rates, disease control and progression‑free survival in heavily pretreated patient populations. Other 6‑K submissions incorporate interim reports for quarterly periods, outlining revenue from collaboration agreements, research and development expenses, cash position and changes in share capital.
On this page, users can review Immatics’ furnished reports to understand how the company characterizes its PRAME franchise, its TCR Bispecific (TCER®) platform and its strategic collaborations with partners such as Moderna, Bristol Myers Squibb and Genmab. The filings also document corporate developments, including leadership appointments and pipeline prioritization decisions.
Stock Titan enhances these filings with AI‑powered summaries that highlight key clinical and financial points from lengthy documents, helping readers quickly identify material updates. Real‑time ingestion from EDGAR means new Immatics 6‑K and 20‑F submissions appear promptly, and investors can also monitor incorporated exhibits such as press releases and investor presentations referenced in the filings.
Baker Bros. Advisors and affiliated persons report beneficial ownership of 10,168,901 ordinary shares of Immatics N.V., representing 8.4% of the company’s outstanding common stock based on 121,550,169 shares outstanding as reported in the issuer's public filing. The reported holdings are held by two funds (Life Sciences and 667) for which the adviser has sole voting and dispositive power, with 9,354,564 shares held by Life Sciences and 814,337 shares held by 667. This filing amends prior Schedule 13G disclosures and clarifies ownership and control relationships among the adviser, its GP and two individual reporting persons.
This Schedule 13G/A reports that Suvretta Capital Management, LLC and Aaron Cowen each have shared beneficial ownership of 12,030,129 ordinary shares of Immatics N.V., representing 9.9% of the class. Averill Master Fund, Ltd. reports shared beneficial ownership of 10,623,778 shares, representing 8.7% of the class. The filing shows no sole voting or sole dispositive power for any reporting person; all listed voting and dispositive power is shared. The filing states the securities are directly owned by advisory clients of Suvretta, and the reporting persons disclaim beneficial ownership except to the extent of pecuniary interest.
Immatics N.V. submitted a Form 6-K as a foreign private issuer to furnish materials related to its second quarter 2025 reporting. The company issued an interim report covering the three- and six-month period ended June 30, 2025, a press release with second quarter 2025 financial results and a business update, and an updated corporate investor presentation.
The interim report is attached as Exhibit 99.1, the press release as Exhibit 99.2, and the presentation as Exhibit 99.3. The interim report and the core portions of this Form 6-K (excluding the press release and presentation) are incorporated by reference into Immatics’ existing Form S-8 and Form F-3 registration statements, meaning those offering documents now formally include this updated interim information.
Wellington Management and related entities report beneficial ownership of 5,318,624 shares of Immatics N.V. common stock, representing approximately 4.38% of the class. The filing discloses no sole voting or dispositive power; voting is held as shared voting power of 4,545,848 shares and shared dispositive power of 5,318,624 shares. These shares are owned of record by clients of Wellington investment advisers.
The statement clarifies the position is held in the ordinary course of business and not for the purpose of changing or influencing control; no client is identified as having the right to dividends or sale proceeds for more than 5% of the class.